The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
(−)-Epigallocatechin- 3 -gallate is a new inhibitor of hepatitis C virus entry
Open accessAbstract
Here, we identify (−)-epigallocatechin- 3 -gallate (EGCG) as a new inhibitor of hepatitis C virus (HCV) entry. EGCG is a flavonoid present in green tea extract belonging to the subclass of catechins, which has many properties. Particularly, EGCG possesses antiviral activity and impairs cellular lipid metabolism. Because of close links between HCV life cycle and lipid metabolism, we postulated that EGCG may interfere with HCV infection. We demonstrate that a concentration of 50 μM of EGCG inhibits HCV infectivity by more than 90% at an early step of the viral life cycle, most likely the entry step. This inhibition was not observed with other members of the Flaviviridae family tested. The antiviral activity of EGCG on HCV entry was confirmed with pseudoparticles expressing HCV envelope glycoproteins E1 and E2 from six different genotypes. In addition, using binding assays at 4°C, we demonstrate that EGCG prevents attachment of the virus to the cell surface, probably by acting directly on the particle. We also show that EGCG has no effect on viral replication and virion secretion. By inhibiting cell-free virus transmission using agarose or neutralizing antibodies, we show that EGCG inhibits HCV cell-to-cell spread. Finally, by successive inoculation of naïve cells with supernatant of HCV-infected cells in the presence of EGCG, we observed that EGCG leads to undetectable levels of infection after four passages. Conclusion : EGCG is a new, interesting anti-HCV molecule that could be used in combination with other direct-acting antivirals. Furthermore, it is a novel tool to further dissect the mechanisms of HCV entry into the hepatocyte.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Tea Polyphenols for Health Promotion
Khan, N., & Mukhtar, H. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.06.011 · Cited by 1,156
Chow, H.-H. S., Cai, Y., Hakim, I. A., Crowell, J. A., Shahi, F., Brooks, C. A., Dorr, R. T., Hara, Y., & Alberts, D. S. (2003) · PubMed · Cited by 706
Treating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Antiviral effect of catechins in green tea on influenza virus
Song, J.-M., Lee, K.-H., & Seong, B.-L. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.06.010 · Cited by 654
Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis
Blanchard, E., Belouzard, S., Goueslain, L., Wakita, T., Dubuisson, J., Wychowski, C., & Rouillé, Y. (2006) · Journal of Virology · doi:10.1128/jvi.00024-06 · Cited by 599
Self-citationResistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Sarrazin, C., & Zeuzem, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.055 · Cited by 504
Flint, M., Maidens, C., Loomis-Price, L. D., Shotton, C., Dubuisson, J., Monk, P., Higginbottom, A., Levy, S., & McKeating, J. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6235-6244.1999 · Cited by 469
Self-citationDubuisson, J., Hsu, H. H., Cheung, R. C., Greenberg, H. B., Russell, D. G., & Rice, C. M. (1994) · Journal of Virology · doi:10.1128/jvi.68.10.6147-6160.1994 · Cited by 425
Self-citationKoutsoudakis, G., Kaul, A., Steinmann, E., Kallis, S., Lohmann, V., Pietschmann, T., & Bartenschlager, R. (2006) · Journal of Virology · doi:10.1128/jvi.02460-05 · Cited by 414
Timpe, J. M., Stamataki, Z., Jennings, A., Hu, K., Farquhar, M. J., Harris, H. J., Schwarz, A., Desombere, I., Roels, G. L., Balfe, P., et al. (2008) · Hepatology · doi:10.1002/hep.21959 · Cited by 389
Inhibition of the infectivity of influenza virus by tea polyphenols
Nakayama, M., Suzuki, K., Toda, M., Okubo, S., Hara, Y., & Shimamura, T. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90008-7 · Cited by 385
Expression of the Zinc-Finger Antiviral Protein Inhibits Alphavirus Replication
Bick, M. J., Carroll, J.-W. N., Gao, G., Goff, S. P., Rice, C. M., & MacDonald, M. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.21.11555-11562.2003 · Cited by 384
Nahmias, Y., Goldwasser, J., Casali, M., van Poll, D., Wakita, T., Chung, R. T., & Yarmush, M. L. (2008) · Hepatology · doi:10.1002/hep.22197 · Cited by 279
Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission
Brimacombe, C. L., Grove, J., Meredith, L. W., Hu, K., Syder, A. J., Flores, M. V., Timpe, J. M., Krieger, S. E., Baumert, T. F., Tellinghuisen, T. L., et al. (2011) · Journal of Virology · doi:10.1128/jvi.01592-10 · Cited by 256
Owen, D. M., Huang, H., Ye, J., & Gale, M. (2009) · Virology · doi:10.1016/j.virol.2009.08.037 · Cited by 234
Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle
Wagoner, J., Negash, A., Kane, O. J., Martinez, L. E., Nahmias, Y., Bourne, N., Owen, D. M., Grove, J., Brimacombe, C., McKeating, J. A., et al. (2010) · Hepatology · doi:10.1002/hep.23587 · Cited by 232
Epigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus
Isaacs, C. E., Wen, G. Y., Xu, W., Jia, J. H., Rohan, L., Corbo, C., Di Maggio, V., Jenkins, E. C., & Hillier, S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00825-07 · Cited by 183
Nrf2 expression modifies influenza A entry and replication in nasal epithelial cells
Kesic, M. J., Simmons, S. O., Bauer, R., & Jaspers, I. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.027 · Cited by 164
New direct‐acting antivirals' combination for the treatment of chronic hepatitis C
Asselah, T., & Marcellin, P. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02411.x · Cited by 157
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
Rocha‐Perugini, V., Montpellier, C., Delgrange, D., Wychowski, C., Helle, F., Pillez, A., Drobecq, H., Naour, F. L., Charrin, S., Levy, S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001866 · Cited by 151
Self-citationKawai, K., Tsuno, N. H., Kitayama, J., et al. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(03)02007-4 · Cited by 146
Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy
Nance, C. L., Siwak, E. B., & Shearer, W. T. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.12.024 · Cited by 118
Recent Advances in Hepatitis C Virus Cell Entry
Bartosch, B., & Dubuisson, J. (2010) · Viruses · doi:10.3390/v2030692 · Cited by 36
Self-citationLi, L., Stillemark-Billton, P., Adiels, C. B., Boström, P., Andersson, L. K., Rutberg, M., Ericsson, J., Magnusson, B., Marchesan, D., Ljungberg, A., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500424-jlr200 · Cited by 32
(1982) · PubMed
Cited by
Bioavailability of Dietary Polyphenols and Gut Microbiota Metabolism: Antimicrobial Properties
Marín, L., Miguélez, E. M., Villar, C. J., & Lombó, F. (2015) · BioMed Research International · doi:10.1155/2015/905215 · Cited by 776
Anti‐infective properties of epigallocatechin‐3‐gallate (EGCG), a component of green tea
Steinmann, J., Buer, J., Pietschmann, T., & Steinmann, E. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12009 · Cited by 559
Huang, Q., Liu, X., Zhao, G., Hu, T., & Wang, Y. (2018) · Animal nutrition · doi:10.1016/j.aninu.2017.09.004 · Cited by 555
Flavonoids: Promising Natural Compounds against Viral Infections
Zakaryan, H., Arabyan, E., Oo, A., & Zandi, K. (2017) · Archives of Virology · doi:10.1007/s00705-017-3417-y · Cited by 534
Antiviral Natural Products and Herbal Medicines
Lin, L.-T., Hsu, W.-C., & Lin, C.-C. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124335 · Cited by 529
Metadata
- Authors
- Calland, N., Albecka, A., Belouzard, S., Wychowski, C., Duverlie, G., Descamps, V., Hober, D., Dubuisson, J., Rouillé, Y., & Séron, K.
- Venue
- Hepatology
- Published
- 2012-03
- Volume
- 55
- Issue
- 3
- Pages
- 720-729
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1964179400
- Cited by
- 279
- References
- 26
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.